MVAC yields 2000000.00% · ABBV yields 3.06%● Live data
📍 MVAC pulled ahead of the other in Year 1
Combined, MVAC + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of MVAC + ABBV for your $10,000?
MotorVac Technologies, Inc. manufactures fuel system cleaning equipment and detergents for gasoline and diesel powered engines. Its core products include the MotorVac CarbonClean System for gasoline engines and the Industrial Diesel Tune System for diesel engines. These systems comprise a fuel system diagnostic and cleaning machine and various proprietary cleaning detergents. The company's products also include the Coolant Clean System, which exchanges virtually all of the used coolant mixture in a vehicle's cooling system within few minutes and the LeakChek System, which is used to detect leaks in the vacuum, exhaust, air injection, evaporator, fuel, oil, cooling, and other automotive systems. Recently, the company introduced the TRANSTECH Transmission Service System, an automatic transmission fluid exchange machine. These products are sold in the automotive, commercial trucking, government (local, state and federal), transit, marine, construction, utility, and industrial markets. The company was founded in 1992 and is based in Santa Ana, California.
Full MVAC Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.